Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 IN PLASTIC CONTAINER versus EPANOVA.
AMINOSYN 3.5% IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution